Valeo Financial Advisors LLC Purchases Shares of 11,741 Takeda Pharmaceutical Co. $TAK

Valeo Financial Advisors LLC purchased a new stake in Takeda Pharmaceutical Co. (NYSE:TAK) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 11,741 shares of the company’s stock, valued at approximately $182,000.

Several other hedge funds have also modified their holdings of TAK. QRG Capital Management Inc. increased its holdings in Takeda Pharmaceutical by 11.8% during the 2nd quarter. QRG Capital Management Inc. now owns 432,654 shares of the company’s stock worth $6,689,000 after purchasing an additional 45,726 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Takeda Pharmaceutical by 105.4% in the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 28,361 shares of the company’s stock valued at $438,000 after purchasing an additional 14,550 shares during the last quarter. Gold Investment Management Ltd. lifted its holdings in shares of Takeda Pharmaceutical by 2.6% in the 2nd quarter. Gold Investment Management Ltd. now owns 100,048 shares of the company’s stock valued at $1,540,000 after purchasing an additional 2,490 shares during the last quarter. HB Wealth Management LLC acquired a new position in Takeda Pharmaceutical during the second quarter worth approximately $199,000. Finally, Sage Rhino Capital LLC increased its position in Takeda Pharmaceutical by 7.9% during the second quarter. Sage Rhino Capital LLC now owns 12,604 shares of the company’s stock worth $195,000 after buying an additional 919 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $13.73 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The stock has a fifty day moving average price of $14.86 and a 200 day moving average price of $14.79. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.69. The company has a market cap of $43.69 billion, a PE ratio of 45.77 and a beta of 0.21.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The company had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

TAK has been the topic of a number of research reports. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Saturday, September 27th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.